Liftstream is an executive search recruitment company in the life sciences sector
Sanofi Genzyme Bioventures announce a brace of deals
Sanofi Genzyme Bioventures announced to financing deals today (Sept 8 – 2015), as it contributed to the financing of Proteostasis Therapeutics, a Series B mezzanine round of $37m to the company developing a cystic fibrosis drug for the orphan disease. The financing in the Cambridge, MA based company was led by Cormorant Asset Management and also included Rock Springs Capital Management. Existing investors New Enterprise Associates, Elan Science One, HealthCare Ventures, Fidelity Biosciences, Novartis Bioventures, Novartis Venture Fund, and Sanofi Genzyme BioVentures also participated in the financing.
M&A Continues to Dominate the Rare Diseases Landscape
Alexion took everyone by surprise in recent weeks by announcing a very sizable acquisition of Boston-based Synageva for $8.4bn. This was a significant deal which will only serve to strengthen valuations of rare disease biotechnology companies, which continue to be in the M&A cross-hairs of both pharmaceutical and big-biotech companies.
Merck announces collaboration with Advaxis
Authored by James Sheppard
Kiadis rides high after positive clinical data
Authored by James Sheppard
Swedish Pharmalink receives Orphan Drug Approval for Busulipo
Authored by James Sheppard
Massachusetts biotech continues to excite with new investments
Authored by Karl Simpson
David Motts’ NEA weighs in on rare diseases
Authored by Karl Simpson
PTC Therapeutics opts for conditional approach in Duchenne
Authored by Paul Foster
Synageva offering LSD patients renewed hope
Authored by James Sheppard